Latest KRYS news

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

Zacks Investment Research · Thu, 03 Sep 2026 12:50:50 -0400

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.

Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference

GlobeNewsWire · Thu, 03 Sep 2026 08:00:00 -0400

PITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026, in New York. Management will take part in a fireside chat scheduled at 3:55 pm ET and host investor meetings throughout the day.

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · Wed, 02 Sep 2026 12:31:10 -0400

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

Zacks Investment Research · Tue, 04 Aug 2026 12:00:36 -0400

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Seeking Alpha · Mon, 03 Aug 2026 14:09:56 -0400

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

Investors Business Daily · Mon, 03 Aug 2026 12:40:09 -0400

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

Krystal Biotech Q2 Earnings Call Highlights

MarketBeat · Mon, 03 Aug 2026 10:05:50 -0400

Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overseas.

Market information is provided for research and visualization and is not investment advice.